Members Only Content

Subscribe to get full access

Free Preview

Pre-commercial drug developers don't have traditional fundamentals to analyze, but investors can estimate the likelihood of clinical development. 7investing Lead Advisors Simon Erickson checks in with Maxx Chatsko on his new quest to build accurate, risk-adjusted net present value (rNPV) models for drug developers.

related news & insights

  • July 10, 2025||0 min||||

    Crocs Deep Dive: July 2025

    Crocs Recommendation Report Crocs Presentation Slides

  • 7investing logo next to the Upstart logo.
    June 12, 2025||0 min||||

    Upstart Deep Dive: June 2025

    Upstart Recommendation Report Upstart Presentation Slides

  • May 30, 2025||0.8 min||||

    7investing Exclusive: A Deep Dive Into Lemonade

    Lemonade (NYSE: LMND) is a new player who's really adding zest to the insurance industry. Its AI-powered underwriting enables it to [...]